1 RNA binding proteins involved in regulation of protein synthesis to initiate biogenesis of secondary tumor in hepatocellular carcinoma in mice.

2 Therapeutic potential of carnosine and its derivatives in the treatment of human diseases.

3 Hepatitis B-Virus Genotype D is Prevalent in a Multi-Ethnic Population of Karachi, Pakistan

4 Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

5 Targeting hepatocellular carcinoma: Synthesis of new pyrazole-based derivatives, biological evaluation, DNA binding, and molecular modeling studies

6 Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular carcinoma risk: A case-control study.

7 Ambovex® as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial

8 Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

9 Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma

10 Intermediate stage hepatocellular carcinoma: a summary review

11 Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

12 Post-translational modifiers of liver kinase B1/serine/threonine kinase 11 in hepatocellular carcinoma

13 Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives

14 Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

15 Weighing the benefits of hepatocellular carcinoma surveillance against potential harms

16 Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

17 Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

18 Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)

19 Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

20 Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance

21 Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

22 Editorial: charting the future of hepatocellular carcinoma publications

23 Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt

24 Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma

25 Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

26 Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

27 Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

28 Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma

29 Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review

30 Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies

31 Screening for hepatocellular carcinoma: patient selection and perspectives

32 Open-label phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L

33 Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives

34 A single institution report of 19 hepatocellular carcinoma patients with bile duct tumor thrombus

35 Needle track seeding after radiofrequency ablation for hepatocellular carcinoma: prevalence, impact, and management challenge

36 Pediatric hepatocellular carcinoma: challenges and solutions

37 Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients

38 Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration

39 Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date

40 GPC-3 in hepatocellular carcinoma: current perspectives

41 Minimally invasive image-guided therapies for hepatocellular carcinoma

42 Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary

43 Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

44 Transarterial radioembolization for hepatocellular carcinoma: a review

45 Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

46 Fibrolamellar hepatocellular carcinoma: current clinical perspectives

47 Role of endoscopic ultrasound in diagnosis and management of hepatocellular carcinoma

48 Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma

49 Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy

50 Whither α-FP in the diagnosis of hepatocellular carcinoma?

51 The androgen receptor as an emerging target in hepatocellular carcinoma

52 Emerging role of Hpo signaling and YAP in hepatocellular carcinoma

53 Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy

54 Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib

55 c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma

56 A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma

57 Emerging role of Toll-like receptor 4 in hepatocellular carcinoma

58 Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors

59 Welcome to Journal of Hepatocellular Carcinoma

60 Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy

61 Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

62 Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments

63 Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models

64 Radiological diagnosis of hepatocellular carcinoma

65 Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma

66 Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

67 Clinical utility of imaging for evaluation of hepatocellular carcinoma

68 Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives

69 New insights on the role of epigenetic alterations in hepatocellular carcinoma

70 Potential immunotherapeutic role of interleukin-2 and interleukin-12 combination in patients with hepatocellular carcinoma

71 Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma

72 Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma

73 Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma

74 Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma

75 A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors

76 Preoperative Neutrophil-to-Lymphocyte Ratio Plus Platelet-to-Lymphocyte Ratio Predicts the Outcomes after Curative Resection for Hepatocellular Carcinoma

77 Segmental Distribution of Hepatocellular Carcinoma Correlates with Microvascular Invasion in Liver Explants Undergoing Transplantation

78 Ambovex® as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial

79 Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

80 Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma

81 Intermediate stage hepatocellular carcinoma: a summary review

82 Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

83 Post-translational modifiers of liver kinase B1/serine/threonine kinase 11 in hepatocellular carcinoma

84 Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives

85 Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

86 Weighing the benefits of hepatocellular carcinoma surveillance against potential harms

87 Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

88 Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

89 Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)

90 Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

91 Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance

92 Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

93 Editorial: charting the future of hepatocellular carcinoma publications

94 Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt

95 Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma

96 Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

97 Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

98 Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

99 Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma

100 Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review

101 Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies

Keyword Connections

Journals

Research Groups

Bibliographies